Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance upgrade on Thursday 4th of May 2017 from 8.00am to 9.00am (BST).

During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 3, 2017
Previous Article Next Article

Comparative studies of oxaliplatin-based platinum(IV) complexes in different in vitro and in vivo tumor models

Author affiliations

Abstract

Using platinum(IV) prodrugs of clinically established platinum(II) compounds is a strategy to overcome side effects and acquired resistances. We studied four oxaliplatin-derived platinum(IV) complexes with varying axial ligands in various in vitro and in vivo settings. The ability to interfere with DNA (pUC19) in the presence and absence of a reducing agent (ascorbic acid) was investigated in cell-free experiments. Cytotoxicity was compared under normoxic and hypoxic conditions in monolayer cultures and multicellular spheroids of colon carcinoma cell lines. Effects on the cell cycle were investigated by flow cytometry, and the capacity of inducing apoptosis was confirmed by flow cytometry and Western blotting. The anti-cancer activity of one complex was studied in vivo in immunodeficient and immunocompetent mice, and the platinum levels in various organs and the tumor after treatment were quantified. The results demonstrate that modification of the axial ligands can improve the cytotoxic potency. The complexes are able to interfere with plasmid DNA, which is enhanced by co-incubation with a reducing agent, and cause cell cycle perturbations. At higher concentrations, they induce apoptosis, but generate only low levels of reactive oxygen species. Two of the complexes increase the life span of leukemia (L1210) bearing mice, and one showed effects similar to oxaliplatin in a CT26 solid tumor model, despite the low platinum levels in the tumor. As in the case of oxaliplatin, activity in the latter model depends on an intact immune system. These findings show new perspectives for the development of platinum(IV) prodrugs of the anticancer agent oxaliplatin, combining bioreductive properties and immunogenic aspects.

Graphical abstract: Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models

Back to tab navigation
Please wait while Download options loads

Supplementary files

Publication details

The article was received on 05 Oct 2016, accepted on 31 Jan 2017 and first published on 16 Feb 2017


Article type: Paper
DOI: 10.1039/C6MT00226A
Citation: Metallomics, 2017,9, 309-322
  • Open access: Creative Commons BY license
  •   Request permissions

    Comparative studies of oxaliplatin-based platinum(IV) complexes in different in vitro and in vivo tumor models

    S. Göschl, E. Schreiber-Brynzak, V. Pichler, K. Cseh, P. Heffeter, U. Jungwirth, M. A. Jakupec, W. Berger and B. K. Keppler, Metallomics, 2017, 9, 309
    DOI: 10.1039/C6MT00226A

    This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material.

    Reproduced material should be attributed as follows:

    • For reproduction of material from NJC:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
    • For reproduction of material from PCCP:
      [Original citation] - Published by the PCCP Owner Societies.
    • For reproduction of material from PPS:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
    • For reproduction of material from all other RSC journals:
      [Original citation] - Published by The Royal Society of Chemistry.

    Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.

Search articles by author